EcoDrugPlus

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSPNYG00000005812
Gene Symbol: F2R
2 Cross references
248 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSPNYG00000005859
Gene Symbol: F2R
2 Cross references
249 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSPNYG00000005833
Gene Symbol: F2R
2 Cross references
248 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSPNYG00000020014
Gene Symbol: F2R
3 Cross references
216 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSPNYG00000009174
Gene Symbol: F3
3 Cross references
199 Possible Orthologues:

Coagulation Factor Vii, Like

Ensembl ID : ENSPNYG00000020366
Gene Symbol: F7L
1 Cross references
78 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSPNYG00000020504
Gene Symbol: F10
1 Cross references
232 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSPNYG00000020412
Gene Symbol: F10
1 Cross references
234 Possible Orthologues:

Coagulation Factor Xi-Like

Ensembl ID : ENSPNYG00000000352
Gene Symbol: LOC102198678
2 Cross references
211 Possible Orthologues:

Coiled-Coil Domain Containing 6

Ensembl ID : ENSPNYG00000002944
Gene Symbol: CCDC6
3 Cross references
207 Possible Orthologues:

Collagenase 3-Like

Ensembl ID : ENSPNYG00000000629
Gene Symbol: LOC102213680
2 Cross references
252 Possible Orthologues:

Colony Stimulating Factor 1 Receptor

Ensembl ID : ENSPNYG00000000485
Gene Symbol: CSF1R
3 Cross references
63 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).